Universita Di Genova

Innate Pharma, S.a.

Innate Pharma S.a.s.

Innate Pharma

University of Genova

Universita Degli Studi Di Genova, Dipartimento Di Medicina Sperimentale

Roberto Biassoni

Alessandro Moretta

Cristina Bottino

Lorenzo Moretta

Maria Cristina Mingari

The invention relates to a novel compound termed NKp30 that is selectively expressed by all mature NK cells and that is involved in human natural cytoxicity as an activatory receptor, to new antibodies that bind to the NKp30 structure, and to the pharmaceutical and medicinal uses thereof.

Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same

p75/AIRM1 is expressed on myeloid cells at stages of differentiation and determination of its presence is useful in monitoring cellular proliferation and determining proliferative states of cells, especially myeloid cells in diseases such as chronic myeloid leukemia. Ligands such as antibody molecules, for instance the QA79 monoclonal antibody deposited under accession number ICLC No. PD99003, are useful for methods of diagnosis and treatment, e.g. by way of inhibition of cellular proliferation and induction of apoptosis in cells.

Methods of diagnosis and treatment by binding p75/AIRM1

The invention relates to polypeptides having a triggering NK activity and an amino acid sequence that is at least 80% identical over its entire length to the polypeptide having SEQ ID NO: 1, and any immunogenic fragments thereof, as well as to the polyclonal and monoclonal antibodies directed against said polypeptides, and immuno-reactive fragments thereof. Application for detecting NK cells in a sample, for their removal from a sample or for enrichment of NK cells, and for NK cell natural cytotoxicity regulation.

Polypeptides having a triggering NK activity and biological applications

The present invention relates to a novel protein, termed NTB-A, nucleic acid molecules encoding the same and uses thereof. The invention also relates to methods of regulating Natural Killer cells activity by regulating the activity of NTBA-A in vitro, ex vivo or in vivo. The invention also comprises methods of screening active compounds using NTB-A or fragments thereof, or nucleic acid encoding the same, or recombinant host cells expressing said polypeptide.

NTB-A, a surface molecule involved in natural killer cells activity

The invention relates to polypeptides having a triggering NK activity and an aminoacid sequence that is at least 80% identical over its entire length to the polypeptide having SEQID N&#xb0;1, and any immunogenic fragments thereof, as well as to the polyclonal and monoclonal antibodies directed against said polypeptides, and immuno-reactive fragments thereof. Application for detecting NK cells in a sample, for their removal from a sample or for enrichment of NK cells, and for NK cell natural cytotoxicity regulation.

Growing community of inventors

Genoa, Italy

Roberto Biassoni